The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer

FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.
Byline
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account